Join the Osteoporosis group to help and get support from people like you.
Osteoporosis News (Page 2)
Related terms: Bone Thinning
Updated Guidelines for Preventing Osteoporosis-Related Fractures Released
TUESDAY, Jan. 14, 2025 – All women 65 and older should continue to be screened for osteoporosis, the nation’s leading preventive health panel says in an updated recommendation. The U.S. Preventive S...
USPSTF Recommends Osteoporosis Screening for Women 65 Years and Older
TUESDAY, Jan. 14, 2025 – The U.S Preventive Services Task Force (USPSTF) recommends osteoporosis screening to prevent osteoporotic fractures for all women aged 65 years and older and for...
Denosumab Increases Cardiovascular Risk in Dialysis-Dependent Patients
TUESDAY, Jan. 7, 2025 – For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse...
Blood Test Might Help Doctors Spot Multiple Diseases
THURSDAY, Dec. 12, 2024 – A blood draw is a typical part of a person's regular check-up. But that blood sample might hold a lot more useful information about a person’s health than doctors are c...
Could the Common Thyroid Medicine Levothyroxine Weaken Bones?
MONDAY, Nov. 25, 2024 – New research suggests that a thyroid medication often prescribed to older Americans may be linked to a common problem in old age – bone loss. Levothyroxine is a synthetic...
RSNA: Levothyroxine Tied to Bone Loss Over Time in Older Adults
MONDAY, Nov. 25, 2024 – Levothyroxine (LT4) use is associated with longitudinal loss of bone mass and density in older adults, according to a study scheduled to be presented at the annual meeting of...
Severe Mental Illness Tied to Fragility Fractures in People 50 Years and Older
FRIDAY, Oct. 25, 2024 – Severe mental illness (SMI) is associated with an increased likelihood of fragility fractures, while osteoporosis may be underdiagnosed, according to a study published online...
FDA Approves Jubbonti (denosumab-bddz), an Interchangeable Biosimilar to Prolia
Basel, March 5, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Jubbonti, (denosumab-bbdz), an i...
Radius Health’s Tymlos (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
Cambridge, Mass., December 20, 2022 – Radius Health, Inc. (“Radius” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Tymlos® (abaloparatide), a parathy...
FDA Approves Bonsity (teriparatide injection) to Treat Osteoporosis
SAN DIEGO, October 7, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA) has approved the new drug application (“NDA”) for Bonsity (PF708) submi...
FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture
April 9, 2019 – The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are...
FDA Approves Prolia (denosumab) for Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia (denosumab) for the treatment...
FDA Approves Tymlos (abaloparatide) for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
WALTHAM, Mass., April 28, 2017 (GLOBE NEWSWIRE) – Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing innovative...
Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle
Miami, FL and New York, NY, – September 24, 2014 – Noven Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication with a new dose of...
FDA Approves Binosto, First and Only Effervescent Osteoporosis Treatment in a Buffered Solution
FREIENBACH, Switzerland, March 14, 2012 /PRNewswire/ – EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved Binosto (alendronate sodium)...